Search
world_patient_safety_day.pdf
Payments_to_patienten_organisations_2020.pdf
What is Pharmacovigilance & its role on Patient Safet.pdf
Stakeholders in Patient Safety & Pharmacovigilance.pdf
Patient advocacy tips for cancer
COPD Patient brochure
Payments_to_patienten_organisations_2022
Harold_and_Dorothy_Patient_Discussion_Guide_Factsheet_0.pdf
Effect_of_Tiotropium_and_Salmeterol_in_COPD_Patients_With .pdf
ischaemic_stroke_protection_as_treatment_priority_for_patients_with_atrial_fibrillation.pdf
PatientPoll_infographic_final.pdf
What is pharmacovigilance & its role on patient safety
What is being done for patient safety by different stakeholder
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.